5569538
Last Update Posted: 2023-05-23
Recruiting
All Genders accepted | 18 Years + |
40 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis
This is an open-label, Phase 2 study of bomedemstat (IMG-7289), an inhibitor of lysine-specific demethylase 1 (LSD1), in combination with JAK inhibition (JAKi) in patients with myelofibrosis.
Eligibility
Relevant conditions:
Myelofibrosis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Harinder Gill, MD
gillhsh@hku.hk
+852 22554542
Data sourced from ClinicalTrials.gov